DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Diphenhydramine Hydrochloride is a drug marketed by Alra, Anabolic, Elkins Sinn, Fosun Pharma, Halsey, Heather, Heritage Pharma, Hikma Intl Pharms, Impax Labs, Ivax Sub Teva Pharms, Lannett, Lederle, LNK, Mk Labs, Mutual Pharm, Newtron Pharms, Nexgen Pharma Inc, Perrigo, Pioneer Pharms, Purepac Pharm, Pvt Form, Roxane, Sun Pharm Industries, Superpharm, Teva, Valeant Pharm Intl, Vangard, Watson Labs, Whiteworth Town Plsn, Bundy, Cenci, Kv Pharm, Naska, Pharm Assoc, App Pharms, Bel Mar, Dr Reddys, Eurohlth Intl Sarl, Hospira, Lyphomed, Micro Labs, Mylan Institutional, West-ward Pharms Int, Wyeth Ayerst, Alpharma Us Pharms, Cumberland Swan, Hi Tech Pharma, Abraxis Pharm, Fresenius Kabi Usa, and Intl Medication. and is included in seventy-four NDAs.
The generic ingredient in DIPHENHYDRAMINE HYDROCHLORIDE is diphenhydramine hydrochloride. There are twenty-three drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the diphenhydramine hydrochloride profile page.
A generic version of DIPHENHYDRAMINE HYDROCHLORIDE was approved as diphenhydramine hydrochloride by WEST-WARD PHARMS INT on December 31st, 1969.
Summary for DIPHENHYDRAMINE HYDROCHLORIDE
Recent Clinical Trials for DIPHENHYDRAMINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
|National Institutes of Health (NIH)||Phase 2|
|Tufts Medical Center||Phase 2|
|Memorial Sloan Kettering Cancer Center||Phase 2|